StreetAlpha.app
Home › Stocks › EXEL

Exelixis, Inc. (EXEL)

Healthcare
$68.50
▲ +2.09%
LAST CLOSE · NOV 17

Exelixis develops and sells cancer medicines, led by CABOMETYX, for physicians and their patients. It last closed at $68.50 on Nov 17, up 2.09% on the day. EXEL reports earnings on Tue, Feb 9, 2027. The average 12-month price target from 8 analysts is $63.25 (-7.7% from the last close), with a high of $78.00 and a low of $54.00. Analyst consensus is Hold, based on the latest ratings from 8 firms (3 buy, 5 hold, 0 sell). Over the past 90 days StreetAlpha recorded 2 whale options trades in EXEL, 50% of them bullish and 50% bearish. In the past 30 days there were 1 dark pool print totaling $823K, the largest $823K.

AI Auto Pilots
Is EXEL in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$2.5B
+9.1% vs a year ago
Net income
$885.1M
+30.6% vs a year ago
EPS (diluted)
$3.34
+40.3% vs a year ago
Free cash flow
$1.2B
46.5% margin
Valuation
Market cap
$16.7B
244.0M shares
P/E
20.5
Price over 12 month EPS
Price to sales
6.7
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$304.8M
At Oct 2
Shareholder equity
$1.8B
Buybacks
$1.3B
Last 12 months
Fiscal year endsJanuary
ExchangeNasdaq
Financials history
FY2021: $1.4B$1.4BFY2021FY2022: $1.6B$1.6BFY2022FY2023: $1.8B$1.8BFY2023FY2025: $2.2B$2.2BFY2025FY2026: $2.3B$2.3BFY2026

From EXEL's SEC filings, latest 10-Q for the period ending Oct 2, 2026 (filed Oct 29). Last 12 months adds up the four latest quarters.

Next report
Feb 9
2027 · Time not announced
Consensus EPS forecast
$1.04
$659.7M revenue est.
Year-ago EPS
—
Not on file
Options-implied move
—
Posted about a week before
Analyst consensus
Hold
Based on 8 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Hold
8firms
3 Buy5 Hold0 Sell
Each firm's latest rating on EXEL in the past 90 days
Average 12-month target
$63.25
▼ 7.7% downside

Based on 8 analysts who set a price target on EXEL in the past 90 days. The average target is $63.25, with a high of $78.00 and a low of $54.00, compared with the last close of $68.50.

Low $54.00Avg $63.25High $78.00
Blue marker: last close $68.50
Highest target$78.00
Average target$63.25
Lowest target$54.00
Latest rating changes
Morgan StanleyTarget lowered
Nov 13Hold$60 → $57
Leerink PartnersMaintained
Nov 5Hold$58
HC Wainwright & Co.Maintained
Nov 2Buy$78
TD CowenMaintained
Oct 30Buy$76
Morgan StanleyTarget raised
Oct 30Hold$53 → $60
DateFirmActionRatingPrice target
Nov 13Morgan StanleyTarget loweredHold$60 → $57
Nov 5Leerink PartnersMaintainedHold$58
Nov 2HC Wainwright & Co.MaintainedBuy$78
Oct 30TD CowenMaintainedBuy$76
Oct 30Morgan StanleyTarget raisedHold$53 → $60
Loading…

Technical Analysis

EXEL · as of the Nov 17 close · updated after every close
Uptrend

The stock is 0% above its 20 day and 9% above its 50 day average. It is 23% above its 200 day average, so the longer trend is still up. Momentum is neutral (RSI 56). The nearest support is the 20 day average at $68.38, and the nearest resistance the Pivot R1 at $69.27.

Short trendBullish
Long trendBullish
MomentumNeutral
StretchNormal
VolatilityHigh, 3.2%/day
Key levels
$73.6952 week high+7.6%
$73.69Swing high (Nov 5)+7.6%
$69.27Pivot R1+1.1%
$68.50Last close
$68.3820 day average−0.2%
$68.01Swing low (Nov 6)−0.7%
$67.77Pivot−1.1%
$67.00Pivot S1−2.2%
$62.6650 day average−8.5%
$58.88100 day average−14.0%
$52.50200 day average−23.4%
$39.7152 week low−42.0%
Indicators
RSI (14)55.78Middle of its rangeNeutral
MACD1.95Below its signal lineBearish
Stochastic38.6Middle of its rangeNeutral
ADX (14)36.5Trending up
Williams %R-60.1Oversold below −80, overbought above −20Neutral
CCI (20)-17.7Oversold below −100, overbought above 100Neutral
Rate of change−5.3%Change over 10 sessionsBearish
ATR (14)$2.18Typical daily range, 3.2% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for EXEL

What happened before

See how EXEL did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow EXEL usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How EXEL has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
2
Bullish
1
50%
Bearish
1
50%
Date span
Aug 27 – Aug 27
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
1
Notional
$823K
Largest print
$823K
Loading…

EXEL Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ●360 buying vs 349 selling
  • ▼Held by funds -5.5 pts
  • ▲Funds holding +14
  • ▼Superinvestors: 0 added, 4 cut
  • ▼Put/call 0.89 to 1.57
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding774760+1.8%
In funds' top 10129+33.3%
Held by funds101.3%106.7%−5.5 pts
New / increased95 / 265123 / 257−5.3%
Reduced / sold out275 / 74280 / 690.0%
Put/call ratio1.570.89+77.1%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See EXEL institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether EXEL is in one of them and how their past EXEL trades turned out.

EXEL in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered EXEL in an article yet. Here's the latest on the wider market.

EXEL Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Feb 5
Who traded EXEL · since 2019
Latest 5 filings of 6
$1K – $15KTraded Jan 10, 2024Filed Feb 5, 2024
$1K – $15KTraded Dec 6, 2022Filed Jan 3, 2023
$1K – $15KTraded Jun 4, 2019Filed Apr 27, 2020
Donna ShalalaSell (partial)
$1K – $15KTraded Apr 16, 2019Filed Apr 27, 2020
$1K – $15KTraded Feb 6, 2019Filed Apr 27, 2020
PersonTypeAmountTradedFiledDelay
Ro KhannaD · CASell$1K – $15KJan 10, 2024Feb 5, 202426 d
Ro KhannaD · CABuy$1K – $15KDec 6, 2022Jan 3, 202328 d
Donna ShalalaD · FLSell$1K – $15KJun 4, 2019Apr 27, 2020328 d
Donna ShalalaD · FLSell (partial)$1K – $15KApr 16, 2019Apr 27, 2020377 d
Donna ShalalaD · FLBuy$1K – $15KFeb 6, 2019Apr 27, 2020446 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Exelixis

Exelixis is a biopharmaceutical company based in Alameda, California, that develops and sells medicines for cancer. Its main product is CABOMETYX, a cabozantinib tablet used to treat several forms of kidney, liver, thyroid and neuroendocrine cancer, and it also sells COMETRIQ for medullary thyroid cancer. Its medicines are prescribed by physicians and taken by patients, with partners such as Ipsen and Takeda handling sales in markets outside the U.S. Its pipeline includes zanzalintinib, which is under review for colorectal cancer.

Headquarters
Alameda, CA
Founded
1994